Literature DB >> 23939894

Contribution of efflux pumps, porins, and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii.

C Rumbo1, E Gato, M López, C Ruiz de Alegría, F Fernández-Cuenca, L Martínez-Martínez, J Vila, J Pachón, J M Cisneros, J Rodríguez-Baño, A Pascual, G Bou, M Tomás.   

Abstract

We investigated the mechanisms of resistance to carbapenems, aminoglycosides, glycylcyclines, tetracyclines, and quinolones in 90 multiresistant clinical strains of Acinetobacter baumannii isolated from two genetically unrelated A. baumannii clones: clone PFGE-ROC-1 (53 strains producing the OXA-58 β-lactamase enzyme and 18 strains with the OXA-24 β-lactamase) and clone PFGE-HUI-1 (19 strains susceptible to carbapenems). We used real-time reverse transcriptase PCR to correlate antimicrobial resistance (MICs) with expression of genes encoding chromosomal β-lactamases (AmpC and OXA-51), porins (OmpA, CarO, Omp33, Dcap-like, OprB, Omp25, OprC, OprD, and OmpW), and proteins integral to six efflux systems (AdeABC, AdeIJK, AdeFGH, CraA, AbeM, and AmvA). Overexpression of the AdeABC system (level of expression relative to that by A. baumannii ATCC 17978, 30- to 45-fold) was significantly associated with resistance to tigecycline, minocycline, and gentamicin and other biological functions. However, hyperexpression of the AdeIJK efflux pump (level of expression relative to that by A. baumannii ATCC 17978, 8- to 10-fold) was significantly associated only with resistance to tigecycline and minocycline (to which the TetB efflux system also contributed). TetB and TetA(39) efflux pumps were detected in clinical strains and were associated with resistance to tetracyclines and doxycycline. The absence of the AdeABC system and the lack of expression of other mechanisms suggest that tigecycline-resistant strains of the PFGE-HUI-1 clone may be associated with a novel resistance-nodulation-cell efflux pump (decreased MICs in the presence of the inhibitor Phe-Arg β-naphthylamide dihydrochloride) and the TetA(39) system.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23939894      PMCID: PMC3811325          DOI: 10.1128/AAC.00730-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  49 in total

1.  Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454.

Authors:  S Magnet; P Courvalin; T Lambert
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Identification of Tet 39, a novel class of tetracycline resistance determinant in Acinetobacter spp. of environmental and clinical origin.

Authors:  Y Agersø; L Guardabassi
Journal:  J Antimicrob Chemother       Date:  2005-03-10       Impact factor: 5.790

3.  AbeM, an H+-coupled Acinetobacter baumannii multidrug efflux pump belonging to the MATE family of transporters.

Authors:  Xian-Zhong Su; Jing Chen; Tohru Mizushima; Teruo Kuroda; Tomofusa Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Sequence-based typing of ade B as a potential tool to identify intraspecific groups among clinical strains of multidrug-resistant Acinetobacter baumannii.

Authors:  Geert Huys; Margo Cnockaert; Alexandr Nemec; Jean Swings
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Cloning and functional analysis of the gene encoding the 33- to 36-kilodalton outer membrane protein associated with carbapenem resistance in Acinetobacter baumannii.

Authors:  Maria del Mar Tomás; Alejandro Beceiro; Astrid Pérez; David Velasco; Rita Moure; Rosa Villanueva; Jesús Martínez-Beltrán; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii.

Authors:  Harald Seifert; Lucilla Dolzani; Raffaela Bressan; Tanny van der Reijden; Beppie van Strijen; Danuta Stefanik; Herre Heersma; Lenie Dijkshoorn
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 7.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

8.  Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina.

Authors:  S Brown; H K Young; S G B Amyes
Journal:  Clin Microbiol Infect       Date:  2005-01       Impact factor: 8.067

9.  Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide.

Authors:  Stefanie Pannek; Paul G Higgins; Petra Steinke; Daniel Jonas; Murat Akova; Jürgen A Bohnert; Harald Seifert; Winfried V Kern
Journal:  J Antimicrob Chemother       Date:  2006-03-10       Impact factor: 5.790

10.  Presence of the Tet M determinant in a clinical isolate of Acinetobacter baumannii.

Authors:  Anna Ribera; Joaquim Ruiz; Jordi Vila
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more
  62 in total

Review 1.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

Review 2.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

3.  Contribution of the TetB Efflux Pump to Minocycline Susceptibility among Carbapenem-Resistant Acinetobacter baumannii Strains.

Authors:  Peng Wang; Christi L McElheny; Roberta T Mettus; Robert M Q Shanks; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 4.  Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.

Authors:  Edward Geisinger; Ralph R Isberg
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

Review 5.  Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for the Rapid Detection of Antimicrobial Resistance Mechanisms and Beyond.

Authors:  Marina Oviaño; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

6.  Biofilm Formation Caused by Clinical Acinetobacter baumannii Isolates Is Associated with Overexpression of the AdeFGH Efflux Pump.

Authors:  Xinlong He; Feng Lu; Fenglai Yuan; Donglin Jiang; Peng Zhao; Jie Zhu; Huali Cheng; Jun Cao; Guozhong Lu
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

7.  L-lysine potentiates aminoglycosides against Acinetobacter baumannii via regulation of proton motive force and antibiotics uptake.

Authors:  Wanyan Deng; Tiwei Fu; Zhen Zhang; Xiao Jiang; Jianping Xie; Hang Sun; Peng Hu; Hong Ren; Peifu Zhou; Qi Liu; Quanxin Long
Journal:  Emerg Microbes Infect       Date:  2020-03-20       Impact factor: 7.163

Review 8.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

Review 9.  Intravenous Minocycline: A Review in Acinetobacter Infections.

Authors:  Sarah L Greig; Lesley J Scott
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

10.  AdeRS combination codes differentiate the response to efflux pump inhibitors in tigecycline-resistant isolates of extensively drug-resistant Acinetobacter baumannii.

Authors:  J-R Sun; C-L Perng; J-C Lin; Y-S Yang; M-C Chan; T-Y Chang; F-M Lin; T-S Chiueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-18       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.